Holen Sie sich die Stockscreener-App
4.655
1.59%
-0.075
Handel nachbörslich:
4.71
0.055
+1.18%
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next - Yahoo! Finance Canada
Assessing Immuneering (IMRX) Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress - simplywall.st
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
Risk Hedge: Can Immuneering Corporation stock deliver strong Q4 earningsJuly 2025 Big Picture & Safe Capital Allocation Plans - ulpravda.ru
Can Immuneering Corporation stock outperform in 2025 bull marketJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - ulpravda.ru
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX) - Seeking Alpha
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink - TipRanks
Stock market today: S&P 500, Dow Jones futures decline — AZZ, Northrop Grumman, Immuneering in focus - MSN
Is Immuneering Corporation stock gaining market shareJuly 2025 Fed Impact & Community Trade Idea Sharing Platform - ulpravda.ru
IMRX Stock Closed Over 20% Higher Today: Here’s Why - Asianet Newsable
Immuneering Pancreatic Cancer Study Reports Promising Survival Results, Yet Shares Decline - Bitget
Why Is Immuneering Stock Trading Lower Today?Immuneering (NASDAQ:IMRX) - Benzinga
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang - TipRanks
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update - TechStock²
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Stock Market Update: S&P 500 and Dow Jones Futures Fall — Spotlight on AZZ, Northrop Grumman, Immuneering - Bitget
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - markets.businessinsider.com
Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3 - Yahoo Finance
IMRX: Atebumetanib plus chemo showed 64% 12-month survival in pancreatic cancer, nearly double standard care - TradingView — Track All Markets
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Immuneering reports 64% survival rate in pancreatic cancer trial - Investing.com
Immuneering stock falls after reporting survival data for pancreatic cancer drug - Investing.com
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data - TipRanks
Immuneering reports 64% survival rate in pancreatic cancer trial By Investing.com - Investing.com Canada
Immuneering Corp Announces Interim Data from Phase 2a Trial - TradingView — Track All Markets
Immuneering reports 64% survival rate at 12 months for pancreatic cancer drug - StreetInsider
Immuneering CorporationClass A Common Stock (NQ: IMRX - FinancialContent
Immuneering signals fiscal strategy with atebimetinib trial progress - Traders Union
Retail Trends: Will Immuneering Corporation stock see insider buyingCEO Change & Detailed Earnings Play Strategies - moha.gov.vn
All you need to know about Immuneering (IMRX) rating upgrade to buy - MSN
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 - Seeking Alpha
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy - Yahoo Finance
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19% - Sahm
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP - TipRanks
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial - Nasdaq
Immuneering to provide 12-month survival data for pancreatic cancer drug - Investing.com
Immuneering to provide 12-month survival data for pancreatic cancer drug By Investing.com - Investing.com South Africa
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - The Manila Times
Wall Street Zen Downgrades Immuneering (NASDAQ:IMRX) to Sell - Defense World
Immuneering on track to dose first patient in pancreatic cancer trial in 2026 - MSN
Pancreatic cancer treatment atebimetinib set for Phase 3 trial - Rare Cancer News
Is Immuneering Corporation stock attractive for income investorsJuly 2025 Update & Stepwise Trade Signal Guides - Улправда
Why Immuneering Corporation stock attracts global investorsGlobal Markets & Accurate Buy Signal Notifications - Улправда
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - The Manila Times
Immuneering to begin Phase 3 trial of pancreatic cancer drug mid-2026 - Investing.com Australia
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026 - Nasdaq
Immuneering stock rises after FDA and EMA align on Phase 3 trial design By Investing.com - Investing.com South Africa
Immuneering stock rises after FDA and EMA align on Phase 3 trial design - Investing.com
Global trial to test drug combo for first-line pancreatic cancer patients - Stock Titan
Immuneering to be added to the Nasdaq Biotechnology Index - TipRanks
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Immuneering (Nasdaq: IMRX) to be added to Nasdaq Biotechnology Index on Dec. 22 - Stock Titan
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):